Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH Clear all
Recruiting Phase 3 Interventional

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
126
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Not applicable Interventional

The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)

NCT02663544
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome, Obesity, Diabetes, NAFLD, Inflammation
Interventions
Limited dairy diet, Low-fat dairy diet, Full-fat dairy diet
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 6:46 PM EDT
Suspended Phase 3 Interventional Results available

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

NCT04104321
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Aramchol free acid, Placebo
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Active, not recruiting Not applicable Interventional

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT04820036
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 20, 2026, 6:46 PM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NCT03748628
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT06947304
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03053063
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
128
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 20, 2026, 6:46 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672866
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 20, 2026, 6:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed No phase listed Observational

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

NCT05669677
View directory record Official record
Conditions
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD, NASH
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03248882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Placebo, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
60
States / cities
Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 20, 2026, 6:46 PM EDT
Not yet recruiting No phase listed Observational

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

NCT06797596
View directory record Official record
Conditions
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
Interventions
Not listed
Lead sponsor
Fibronostics USA, Inc
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Timeline
2025
U.S. locations
1
States / cities
Lady Lake, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

NCT02684591
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, HIV
Interventions
Aramchol, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NCT03207425
View directory record Official record
Conditions
NASH
Interventions
EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 20, 2026, 6:46 PM EDT
Terminated No phase listed Observational

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

NCT03479125
View directory record Official record
Conditions
Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 20, 2026, 6:46 PM EDT
Active, not recruiting Not applicable Interventional

Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

NCT04383951
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
Dietary consult for participants in the ketogenic diet arm, Dietary consult for participants in the standard of care arm
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed No phase listed Observational

Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry)

NCT04336800
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Interventions
LiverMultiscan
Device
Lead sponsor
Perspectum
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 20, 2026, 6:46 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Interventions
GSK4532990, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
80
States / cities
Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 6:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

NCT03858920
View directory record Official record
Conditions
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Fibroscan of Liver, Low-dose non-contrast CT
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 20, 2026, 6:46 PM EDT
Terminated Phase 1 Interventional

Study of Fish Oil to Reduce ALT Levels in Adolescents

NCT00694746
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 20, 2026, 6:46 PM EDT
Completed Not applicable Interventional

Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan

NCT04671186
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Culturelle (Lactobacillus rhamnosus strain GG), Placebo
Dietary Supplement · Other
Lead sponsor
Northwell Health
Other
Eligibility
5 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 20, 2026, 6:46 PM EDT